← Russell 3000 cross-section

OKUR OnKure Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$156m
Revenue TTM
$3m
Net income TTM
$-59m
Free cash flow
$-48m
Composite score
Sector rank
#2949

Valuation

P / E
EV / EBITDA
EV / sales
-6.0
FCF yield
-30.70%
Earnings yield vs 10-yr
-42.38pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-1,709.0%
EBITDA margin
-1,797.3%
ROE
-34.1%
ROIC
Revenue growth

Insider activity, last 90 days

Net open-market
$-0.00m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of Reneo’s initial public offering, (b) in which we have total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which requires, among other things, that the market value of our Class A Common Stock that is held by non-affiliates to exceed $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1 billion in non-convertible debt during the prior three-year period.OnKure Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →